Welcome to the Working Group on New TB Drugs Blog
Posted in TB Prevention and Control Strategies, Video, Voices from the Fight to Stop Tuberculosis
Video: Global Fund Impact in Indonesia
This video presents interviews with a diverse range of stakeholders on the positive impact that Global Fund financing has had for Indonesia’s national programme. This post also includes another perspective from Kenya.
Posted in Action, Announcements, Events, TB News, TB Prevention and Control Strategies, TB Treatment
Call to Action–Save a million lives by 2015
On June 6, 2011, the Stop TB Partnership launched the initiative Time to Act–Save a Million Lives by 2015 at the UN Headquarters at a reception hosted by Ray Chambers, the UN Secretary-General’s Special Envoy for Malaria and UN MDG Advocate. If you would like to respond to this call to action, visit www.action.org.
Posted in TB Prevention and Control Strategies, TB Treatment, Voices from the Fight to Stop Tuberculosis, WGND Podcast Series
TB R&D Weekly Update: Podcast Interview with Armand Van Deun
This week’s interview is with Dr. Armand Van Deun who was the recipient of the 2010 Stop TB Partnership-Kochon Foundation prize. Last year, Dr. Van Deun, et al., published an article in the American Journal of Respiratory and Critical Care Medicine entitled “Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis”. In the interview, we discuss this article which presents the results of an observational study in Bangladesh of a treatment for multidrug-resistant TB that incorporates fourth-generation fluoroquinolone combined with other second-line drugs and supplemented by potentially still active first-line drugs. Additional links to TB R&D News are included.
Posted in Announcements, market access, TB News, TB Prevention and Control Strategies, TB Treatment, Video
Private TB Drug Market is Larger than Expected
The first detailed study of the private tuberculosis (TB) drug market, published on May 4th, in the PLoS ONE journal, finds that the market is surprisingly large, and has irregular practices that could be driving treatment failures and contributing to the emergence of multidrug-resistant TB (MDR-TB).
TB R&D Weekly Update: 4-Drug Fixed Dose Combination Shows Comparable Efficacy and Safety
In this week’s article, we present a summary of this article by Christian Lienhardt (Leader of the Clinical Trial Capacity Subgroup, and affiliated with the Stop TB Partnership), et al., on the efficacy and safety of a 4-drug FDC when compared to a regimen of separately administered drugs. Additional links to TB R&D News are included.
Posted in Regulations and Guidelines, TB Drug Development, TB Prevention and Control Strategies, TB Treatment
TB R&D Weekly Update: Promoting Fixed-dose Combos for TB control
In this week’s article, Monedero and Caminero conduct a critical review of research on the use of fixed-dosed combinations (FDCs) for tuberculosis with the conclusion that FDCs should continue to be promoted and recommended. Additional links to TB R&D News are included.
TB R&D Weekly Update: Combined Isoniazid and Antiretroviral Therapy Protects HIV-infected Children
In this week’s TB R&D update, the focus is on pediatrics and tuberculosis with several studies published on the subject. Frigati, et al., wanted to determine if isoniazid preventive therapy (IPT) combine with antiretroviral therapy (ART) would reduce TB in HIV-infected children. The article is published online ahead of print this month in Thorax and is entitled “The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting.” Also, links to additional news in TB R&D are included.
Posted in Announcements, Regulations and Guidelines, TB Prevention and Control Strategies, TB Treatment
New Report on Drugs for Drug-resistant TB
The Médecins Sans Frontières and The Union will release on World TB Day a new report entitled “DR-TB drugs under the microscope” outlining drugs currently available to treat drug-resistant tuberculosis (DR-TB) including product information, sources of the drug, quality status, and price.
Posted in Front Lines of TB R&D, TB Drug Development, TB Prevention and Control Strategies, TB Treatment
TB R&D Weekly Update: Recommended Dose of Pyrazinamide Could Be Inadequate
In this week’s TB R&D update, we look at the whether higher does of pyrazinamide may result in better treatment outcomes for TB patients. The research is published at the end of January online ahead of print in the Antimicrobial Agents and Chemotherapy journal and is entitled “Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis.” Also, links to additional news in TB R&D are included.
Posted in Early Drug Development, Front Lines of TB R&D, TB News, TB Prevention and Control Strategies
TB R&D Weekly Update: TB Vaccine Demonstrates Protection Pre- and Post-exposure
In this week’s TB R&D update, we look at a novel vaccine that shows protection against TB before and after exposure. The research is published in the January issue of Nature Medicine and is entitled “A multistage tuberculosis vaccine that confers efficient protection before and after exposure”. Also, links to additional news in TB R&D are included.
-
You are currently browsing the archives for the TB Prevention and Control Strategies category.
-
Toppix TB News- Calif. Man Is Criminally Charged to Force Compliance with Tuberculosis Treatment Plan 18 May 2012
- Indian Hospital patients share stories to help heal 17 May 2012
- West Springfield women honored for working with immigrants to prevent tuberculosis 15 May 2012
- MSF says additional resources needed to improve ART access in Burma 11 May 2012
- World disease fund gets added $1.6 bln shot in arm 9 May 2012
